Protean Presents on Key Genetic Characteristics of Pediatric AML Between Black/African Americans and Caucasians
Protean Presents on Key Genetic Characteristics of Pediatric AML Between Black/African Americans and Caucasians.
Acute Myeloid Leukemia (AML) constitutes 15-20% of all pediatric acute leukemias, with an average survival rate of 70%. However, the black/African American subgroup do significantly worse than whites with AML. Molecular differences such as gene alterations, mRNA expression and methylation were analyzed for pediatric AML cases. Several molecular differences were observed, such as the upregulated olfactory gene alterations in black/African Americans; olfactory genes have been known to be overexpressed in a variety of cancers, and researchers are showing interest in its potential for targeted therapy.
This abstract was originally presented on May 5th at ASPHO.
About Protean BioDiagnostics
Protean BioDiagnostics is revolutionizing modern healthcare with our Protean MAPS™ system, which integrates health screening, diagnostics, treatment guidance, and tele-medicine backed decision support.
We collaborate with physicians and health groups to support them in providing the best possible care for their patients, regardless of where they live.